Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
EPO (human):Fc (human) (rec.) (non-lytic)
430
CHF
CHF 430.00
In stock
CHI-HF-220EPO-C05050 µgCHF 430.00
| Product Details | |
|---|---|
| Synonyms | Erythropoietin; Epoetin |
| Product Type | Protein |
| Properties | |
| Source/Host | CHO cells |
| Sequence |
The extracellular domain of human EPO (aa 30-193) is fused to the N-terminus of the Fc region of a mutant human IgG1. |
| Crossreactivity | Human |
| Biological Activity |
Measured by the dose-dependant stimulation of human megakaryoblastic leukemia cells. |
| Purity | ≥98% (SDS-PAGE) |
| Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
| Reconstitution | Reconstitute at 100μg/ml in sterile PBS. |
| Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
| Protein Negative Control | |
| Other Product Data |
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC). |
| Declaration | Manufactured by Chimerigen. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Erythropoietin is the principal hormone involved in the regulation of erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells and the maintenance of a physiological level of circulating erythrocyte mass. It is a glycoprotein produced primarily by the kidney. The biological effects of EPO are mediated by the erythropoietin receptor (Epo R). Genetic variations in EPO is associated with susceptibility to microvascular complications of diabetes type 2 (MVCD2) (including diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease and diabetic neuropathy). It is used for the treatment of anemia and misused as a performance-enhancing drug in endurance athletes.